Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Celiac Disease
NCT04704843Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of guselkumab in celiac disease (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Treatment-emergent Adverse Events and Number of Participants with Treatment-emergent Serious Adverse Events. Planned start Jun 2021; status: withdrawn.
02
Drugs
guselkumab
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT04704843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04704843.